J3L-MC-EZEF:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509190-23-00

Acronym

J3L-MC-EZEF

Enrollment

4175

Registered

2024-05-09

Start date

2024-09-03

Completion date

Unknown

Last updated

2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Cardiovascular Disease Elevated lp(a)

Brief summary

1. Time to First Occurrence Any Component of Major Adverse Cardiac Event (MACE)-4

Interventions

DRUG0.9% sodium chloride

DRUGLepodisiran

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. Time to First Occurrence Any Component of Major Adverse Cardiac Event (MACE)-4	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026